Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10957480 | 0.82 | POLB (0.40) | CXCL8 | |
| SCHEMBL4794475 | 0.81 | PTGER3 (0.33) | PARP10 | |
| SCHEMBL29201981 | 0.79 | PTGS1 (0.37) | — | |
| SCHEMBL5624661 | 0.78 | — | — | |
| SCHEMBL29168145 | 0.75 | CHRM2 (0.30) | — | |
| SCHEMBL29168146 | 0.75 | CHRM2 (0.30) | — | |
| SCHEMBL27598745 | 0.74 | — | — | |
| SCHEMBL29024217 | 0.74 | PTGER3 (0.33) | — | |
| Carbamic Acid SCHEMBL29168073 | 0.73 | — | — | |
| SCHEMBL3421177 | 0.73 | ALOX5 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | claimed |
| EP-4214197-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2022060812-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2011161615-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-29 | — | — | WO | claimed |
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | disclosed |
| EP-4125846-A4 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | University of Tennessee Research Foundation (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-04-13 | — | — | US | disclosed |
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-04-13 | — | — | US | disclosed |
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-04-13 | — | — | US | disclosed |
| CN-115701991-A | Pyrazolylpropionamide compounds and their use for treating prostate cancer | 田纳西大学研究基金会 | 2023-02-14 | — | — | CN | disclosed |
| CN-115701991-A | Pyrazolylpropionamide compounds and their use for treating prostate cancer | 田纳西大学研究基金会 | 2023-02-14 | — | — | CN | disclosed |
| EP-4125846-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | University of Tennessee Research Foundation (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4125846-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | University of Tennessee Research Foundation (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4125846-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | University of Tennessee Research Foundation (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202936-A9 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021202936-A9 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021202936-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202936-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | AR, KLK3, ACP3 | EPHX1 4160/4885PARP10 128/4885CXCL8 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.